Dozens of patients in the United States have filed personal injury lawsuits against the makers of popular GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, alleging that the companies failed to adequately warn about a potential risk of sudden vision loss.
The lawsuits relate to non-arteritic anterior ischemic optic
neuropathy (NAION), a rare condition that can lead to significant and, in some
cases, permanent vision loss. The cases against Novo Nordisk, the maker of
Ozempic and Wegovy, and Eli Lilly, the maker of Mounjaro and Zepbound, have
been consolidated into a multi-district federal lawsuit in Pennsylvania.
The plaintiffs maintain that the companies knew or should have
known about the potential link between these drugs and NAION and failed to
provide sufficient warnings to patients and medical professionals. However, the
lawsuits contain allegations that still need to be proven in court, and the
companies have denied any proven causal link between their medications and the
disease.
The concern has also reached regulatory agencies. The FDA
has indicated that it is evaluating whether any regulatory action is necessary
regarding the potential association between GLP-1 drugs and NAION.
The litigation continues as authorities and specialists
analyze the available scientific evidence on the potential eye risks associated
with these popular diabetes and weight-management treatments.